Saturday 17 October 2026 Export CVRX’s income statement to Excel — free account

CVRx, Inc.

CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024. In the quarter to June 2026, revenue grew 15.6%, EPS grew 7.02%, free cash flow fell 11.2% and total debt rose 18.6%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

1.30 0.09 −6.47%

Follow CVRX

Alert me

Market cap: $37.0M
P/E: 0.0×
Fwd P/E: −2.7×
Dividend yield: —
F-score: 4/9
Altman Z: −6.26
Beneish M: −3.03
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.38

Total sells 0.99

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	2	—	—	—	—	—	1	—	—
Sell	5	—	—	—	5	—	—	—	—	1	—	—

Insider Ownership 38.90%

Capital & Financial Ratios $m

Market Cap 37.03

Revenue 61.19

Net Income (51.97)

Free Cash Flow (41.05)

Net Debt (6.01)

Current Ratio 8.04

Debt/Equity 2.94

P/E ratio 0.00

Fwd P/E (2.74)

P/S ratio 0.56

P/B ratio 1.73

Past 5Y EPS Growth —

This Y EPS Growth 1.38%

Next Y EPS Growth 3.89%

Next Y revenue growth 3.88%

Next 5Y EPS Growth 5.35%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 0.08%

10-year low 10-year high

P/B against its own 10 years 18.86%

10-year low 10-year high

EV/Sales against its own 10 years 0.87%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	91	106	76	65
Receivables	8	9	11	9
Inventory	11	12	12	13
Other	—	—	—	—
	112	130	102	89

	2023	2024	2025	Q'26
Payables	2	3	4	4
ST’ Debt	—	—	—	—
Other	—	—	—	—
	8	11	13	11

Compound Annual Growth %

	10y	5y	3y
Sales	—	56.40%	36.11%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	1.37%	(28.85%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	15	16	—	—	—
’25	12	14	15	16	57
’24	11	12	13	15	51
’23	8	10	11	11	39
’22	4	5	6	7	22
’21	3	3	3	4	13
’20	2	1	1	—	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	—	—	—
’25	(13)	(8)	(10)	(10)	(40)
’24	(11)	(10)	(10)	(8)	(39)
’23	(10)	(13)	(8)	(8)	(39)
’22	(11)	(10)	(11)	(11)	(43)
’21	(5)	(6)	(9)	(7)	(28)
’20	(5)	(7)	(5)	(4)	(16)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	—	—	—
’25	(13)	(8)	(10)	(10)	(41)
’24	(12)	(10)	(10)	(8)	(41)
’23	(10)	(13)	(8)	(8)	(40)
’22	(11)	(10)	(11)	(11)	(43)
’21	(5)	(7)	(9)	(8)	(29)
’20	(5)	(7)	(5)	(4)	(16)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.50)	(0.53)	—	—	—
’25	(0.53)	(0.57)	(0.49)	(0.46)	(2.04)
’24	(1.04)	(0.65)	(0.57)	(0.43)	(2.65)
’23	(0.55)	(0.56)	(0.43)	(0.44)	(1.99)
’22	(0.49)	(0.54)	(0.48)	(0.51)	(2.02)
’21	(23.92)	(48.48)	(0.30)	(0.52)	(4.16)
’20	(0.19)	(10.19)	(8.96)	—	(36.46)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	—	10.11	4.60	6.57	6.40	4.30	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	—	29.00	18.84	33.14	32.43	18.55
People
People	Employees	—	—	—	—	63	109	160	200	206	223
	Revenue/emp, $m	—	—	—	0.00	0.10	0.12	0.14	0.20	0.25	0.25
Income, $m
Income, $m	Revenue	—	—	—	6	6	13	22	39	51	57
	Gross margin, %	—	—	—	72.21	76.21	72.08	77.75	84.08	83.75	85.33
	EBT	—	—	—	(15)	(14)	(43)	(41)	(41)	(60)	(53)
	EBT margin, %	—	—	—	(232.70)	(231.69)	(329.76)	(183.89)	(104.47)	(116.80)	(94.13)
	Net income	—	0	—	(15)	(14)	(43)	(41)	(41)	(60)	(53)
	Depreciation	—	—	—	0	0	0	0	1	1	1
Per share, $
Per share, $	Revenue	—	—	—	0.32	15.64	1.26	1.09	1.89	2.27	2.17
	Earnings	—	—	—	(0.76)	(36.46)	(4.16)	(2.02)	(1.99)	(2.65)	(2.04)
	Cash flow	—	—	—	(0.66)	(41.59)	(2.68)	(2.08)	(1.88)	(1.73)	(1.54)
	Capex	—	—	—	0.00	(0.80)	(0.11)	(0.03)	(0.03)	(0.06)	(0.02)
	Free cash flow	—	—	—	(0.66)	(42.40)	(2.79)	(2.11)	(1.91)	(1.79)	(1.56)
	Book value	—	—	—	(14.46)	94.95	14.09	5.32	3.66	3.14	1.51
	Shares, m	—	—	—	19	0	10	21	21	23	26
Valuation, ×
Valuation, ×	P/E	—	—	—	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	—	—	—	1.25	1.25	9.72	17.12	16.10	5.58	3.27
	P/B	—	—	—	0.00	0.00	0.87	3.52	8.33	4.03	4.71
	EV/Sales	—	—	—	(2.12)	(2.12)	0.32	12.84	14.63	4.54	2.87
	EV/FCF	—	—	—	0.81	0.81	(0.14)	(6.65)	(14.51)	(5.75)	(3.98)
Cash, $m
Cash, $m	Operating cash flow	—	—	—	(13)	(16)	(28)	(43)	(39)	(39)	(40)
	Capex	—	—	—	0	0	(1)	(1)	(1)	(1)	(1)
	Free cash flow	—	—	—	(13)	(16)	(29)	(43)	(40)	(41)	(41)
Balance, $m
Balance, $m	Working capital	—	—	—	20	56	145	115	104	119	88
	Total debt	—	—	—	299	19	—	7	29	49	50
	Net debt	—	—	—	273	(40)	(142)	(99)	(61)	(57)	(26)
	Shareholders’ equity	—	—	—	(279)	37	146	109	76	71	39
Returns, %
Returns, %	ROA	—	—	—	(100.64)	(30.52)	(39.64)	(29.86)	(34.31)	(48.23)	(44.76)
	ROIC	—	—	—	0.00	0.00	(417.55)	(273.09)	(184.52)	(258.29)	(244.03)
	ROE	—	—	—	5.12	5.01	58.50	(32.47)	(44.51)	(81.58)	(96.59)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SRTS Sensus Healthcare, Inc.	$45.6M	— (loss-making)	— (loss-making)	−68.69% (below 0%: shrinking)	n/m	−201.65% (below 0%: shrinking)	33.58%	(138.86%)	Compare
TELA TELA Bio, Inc.	$45.6M	— (loss-making)	— (loss-making)	−4.49% (below 0%: shrinking)	n/m	−17.72% (below 0%: shrinking)	72.77%	(48.12%)	Compare
SNWV Sanuwave Health Inc.	$44.5M	3.0×	— (loss-making)	−3.13% (below 0%: shrinking)	n/m	+86.75% (above 0%: growing)	76.23%	(2.88%)	Compare
XTNT Xtant Medical Holdings, Inc.	$42.5M	— (loss-making)	— (loss-making)	−34.96% (below 0%: shrinking)	n/m	−881.96% (below 0%: shrinking)	57.88%	(39.81%)	Compare
RPID Rapid Micro Biosystems, Inc.	$42.4M	— (loss-making)	— (loss-making)	+10.91% (above 0%: growing)	n/m	−23.97% (below 0%: shrinking)	15.05%	(152.99%)	Compare
NNOX Nano-X Imaging Ltd.	$38.6M	— (loss-making)	— (loss-making)	+36.71% (above 0%: growing)	n/m	−21.37% (below 0%: shrinking)	(1,050.87%)	(1,334.91%)	Compare
CVRX CVRx, Inc.	$37.0M	— (loss-making)	— (loss-making)	+15.57% (above 0%: growing)	n/m	−11.18% (below 0%: shrinking)	87.39%	(82.92%)
ELUT Elutia Inc.	$34.9M	0.6×	— (loss-making)	−11.65% (below 0%: shrinking)	n/m	−2.52% (below 0%: shrinking)	59.62%	(327.85%)	Compare
QTI QT Imaging Holdings, Inc.	$34.8M	— (loss-making)	— (loss-making)	+103.20% (above 0%: growing)	n/m	−236.31% (below 0%: shrinking)	41.16%	(25.07%)	Compare
Median of peers	$42.4M	—	—	−3.81%	—	−22.67%	49.52%	(93.49%)

All 149 Medical Devices stocks →

CVRx, Inc. (CVRX) key facts

Concern: CVRx, Inc. reported a net loss of $53.3 million, or a loss of $2.04 per share, for fiscal 2025.
Strength: CVRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $56.7 million, up 10.4% from fiscal 2024.
CVRx, Inc. (CVRX) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CVRX traded at $1.30, a market capitalization of $37.0 million.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 0.6× sales.
Return on equity was −96.6% and debt-to-equity 2.94.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −6.26 (distress zone) for fiscal 2025.